Efficacy and safety of daratumumab in the treatment of relapsed ...

Our results suggest that daratumumab-based regimens are effective in the treatment of RRMM, improving progression-free survival, ...

Conclusion: Our results suggest that daratumumab-based regimens are effective in the treatment of RRMM, improving progression-free survival, ...

Efficacy and Safety of Daratumumab, Pomalidomide and ...

Conclusion: This is the first and largest reported study of DPd vs DKd for daratumumab naïve patients in a real-world setting. Both DPd and DKd ...

Efficacy and Safety of Daratumumab with Dexamethasone in ...

Daratumumab, an IgG1 κ human monoclonal antibody that targets CD38, has shown efficacy and a favorable safety profile in pts with relapsed or refractory MM ( ...

Efficacy and safety of daratumumab (DARA) in pediatric and young ...

Background: Approximately 15-20% of pediatric pts with ALL or LL will be refractory to/relapse after frontline treatment; relapsed disease ...

Efficacy and safety of daratumumab in the treatment of multiple ...

The available evidence demonstrated that the clinical application of combination regimens containing daratumumab improved the efficacy in patients with MM and ...

Efficacy and Safety of Daratumumab with Dexamethasone in ...

Daratumumab, an IgG1 κ human monoclonal antibody that targets CD38, has shown efficacy and a favorable safety profile in pts with relapsed or ...

Meta-analysis of the efficacy and safety of daratumumab in the ...

The meta-analysis results revealed that compared with conventional treatment, daratumumab significantly improved CR among patients with MM (OR = ...

Efficacy and safety of daratumumab in treatment of relapsed

Conclusion：Daratumumab is effective and safe in the treatment of relapse／refractory AL with high hematological response rate, and the organ ...

Daratumumab provides a survival benefit in relapsed and refractory ...

These results indicated daratumumab is an effective and relative safe treatment in patients with relapsed or refractory MM. A growing body of ...

Efficacy of daratumumab monotherapy in real-world heavily ...

Daratumumab is a promising new agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its clinical activity and ...

Updated subgroup analysis of POLLUX based on cytogenetic risk.

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of ...

a phase 1, dose-escalation study (MMY1003) - SpringerLink

Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed ... daratumumab treatment cycles, with 24 (51.1%) patients ...

Comparison of daratumumab-based regimens as second-line ...

Several clinical trials have evaluated daratumumab-based regimens in patients with relapsed/refractory MM, demonstrating significant ...

Efficacy and safety of daratumumab, pomalidomide, and ...

A vast majority (80%) of patients had lenalidomide refractory disease and nearly 50% had bortezomib refractory disease. The overall response and ...

results from the randomized, open-label, phase III LIGHTHOUSE study

Overall response rate (ORR) was 59% in the melflufen group versus 30% in the daratumumab group (P=0.0300). The most common grade ≥3 treatment- ...

Efficacy and safety of daratumumab with dexamethasone in patients ...

Objective: Patients (pts) with multiple myeloma (MM) and severe renal impairment (RI) have poorer overall survival. Daratumumab (DARA), an IgG1κ human ...

Daratumumab for the Management of Newly Diagnosed ... - Frontiers

Daratumumab-based three-drug regimens or as single-agent are treatment options highly efficacious in relapsed/refractory multiple myeloma (RRMM) ...

Real-world data on the efficacy and safety of daratumumab ...

We confirmed in a real-world setting that daratumumab is an effective treatment option for relapsed/refractory MM with acceptable safety profile ...

Clinical Efficacy and Safety of Daratumumab in the Treatment of ...

Background: Multiple myeloma will relapse in the majority of such patients as there is no cure for it.Daratumumab, a CD38 human monoclonal antibody, ...